<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /><meta http-equiv="Content-Language" content="en" /><title>Verbatim report of proceedings - Transparency of measures regulating the prices of medicinal products for human use (A7-0015/2013 - Antonyia Parvanova) - Wednesday, 6 February 2013</title><meta name="title" content="Verbatim report of proceedings - Transparency of measures regulating the prices of medicinal products for human use (A7-0015/2013 - Antonyia Parvanova) - Wednesday, 6 February 2013" /><meta name="language" content="en" /><meta name="robots" content="index, follow, noodp, noydir, notranslate" /><meta name="copyright" content="© European Union, 2013 - Source: European Parliament" /><meta name="available" content="06-02-2013" /><meta name="sipade-leg" content="7" /><meta name="sipade-type" content="CRE" /><meta property="og:title" content="Verbatim report of proceedings - Transparency of measures regulating the prices of medicinal products for human use (A7-0015/2013 - Antonyia Parvanova) - Wednesday, 6 February 2013" /><meta property="og:image" content="https://www.europarl.europa.eu/website/common/img/icon/sharelogo_facebook.jpg" /><link rel="canonical" href="https://www.europarl.europa.eu/doceo/document/CRE-7-2013-02-06-ITM-008-03_EN.html" /><link href="/doceo/data/css/style_common.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_common_print.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_sipade.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_activities.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/common_sides.css" type="text/css" rel="stylesheet" /><link href="/doceo/data/css/style_sipade_oj_sched.css" type="text/css" rel="stylesheet" />
<script src="/doceo/data/js/overlib.js" type="text/javascript"> </script>
<script src="/doceo/data/js/swap_images.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade.js" type="text/javascript"> </script>
<script src="/doceo/data/js/jquery-1.4.4.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade-OJ-SYN.js" type="text/javascript"> </script><!--ATI analytics script--><script type="text/javascript" data-tracker-name="ATInternet" defer data-value="/website/webanalytics/ati-doceo.js" src="//www.europarl.europa.eu/website/privacy-policy/privacy-policy.js" ></script></head><body bgcolor="#FFFFFF"><div id="overDiv" style="position:absolute; visibility:hidden; z-index:1000;"> </div><a name="top"></a><table cellpadding="0" cellspacing="0" border="0" width="100%"><tr><td><div id="header_sides" class="new">
<a href="/portal/en"><img alt="Go back to the Europarl portal" title="Go back to the Europarl portal" src="/doceo/data/img/EP_logo_neg_EN.png" /></a><h3 class="ep_hidden">Choisissez la langue de votre document :</h3><ul class="language_select">
            <li><a title="bg - български" class="bg on" href="/doceo/document/CRE-7-2013-02-06-ITM-008-03_BG.html">bg - български</a></li>
            <li><a title="es - español" class="es on" href="/doceo/document/CRE-7-2013-02-06-ITM-008-03_ES.html">es - español</a></li>
            <li><a title="cs - čeština" class="cs on" href="/doceo/document/CRE-7-2013-02-06-ITM-008-03_CS.html">cs - čeština</a></li>
            <li><a title="da - dansk" class="da on" href="/doceo/document/CRE-7-2013-02-06-ITM-008-03_DA.html">da - dansk</a></li>
            <li><a title="de - Deutsch" class="de on" href="/doceo/document/CRE-7-2013-02-06-ITM-008-03_DE.html">de - Deutsch</a></li>
            <li><a title="et - eesti keel" class="et on" href="/doceo/document/CRE-7-2013-02-06-ITM-008-03_ET.html">et - eesti keel</a></li>
            <li><a title="el - ελληνικά" class="el on" href="/doceo/document/CRE-7-2013-02-06-ITM-008-03_EL.html">el - ελληνικά</a></li>
            <li class="en selected" title="en - English">en - English<span> (Selected)</span></li>
            <li><a title="fr - français" class="fr on" href="/doceo/document/CRE-7-2013-02-06-ITM-008-03_FR.html">fr - français</a></li>
            <li class="ga" title="ga - Gaeilge">ga - Gaeilge</li>
            <li class="hr" title="hr - hrvatski">hr - hrvatski</li>
            <li><a title="it - italiano" class="it on" href="/doceo/document/CRE-7-2013-02-06-ITM-008-03_IT.html">it - italiano</a></li>
            <li><a title="lv - latviešu valoda" class="lv on" href="/doceo/document/CRE-7-2013-02-06-ITM-008-03_LV.html">lv - latviešu valoda</a></li>
            <li><a title="lt - lietuvių kalba" class="lt on" href="/doceo/document/CRE-7-2013-02-06-ITM-008-03_LT.html">lt - lietuvių kalba</a></li>
            <li><a title="hu - magyar" class="hu on" href="/doceo/document/CRE-7-2013-02-06-ITM-008-03_HU.html">hu - magyar</a></li>
            <li><a title="mt - Malti" class="mt on" href="/doceo/document/CRE-7-2013-02-06-ITM-008-03_MT.html">mt - Malti</a></li>
            <li><a title="nl - Nederlands" class="nl on" href="/doceo/document/CRE-7-2013-02-06-ITM-008-03_NL.html">nl - Nederlands</a></li>
            <li><a title="pl - polski" class="pl on" href="/doceo/document/CRE-7-2013-02-06-ITM-008-03_PL.html">pl - polski</a></li>
            <li><a title="pt - português" class="pt on" href="/doceo/document/CRE-7-2013-02-06-ITM-008-03_PT.html">pt - português</a></li>
            <li><a title="ro - română" class="ro on" href="/doceo/document/CRE-7-2013-02-06-ITM-008-03_RO.html">ro - română</a></li>
            <li><a title="sk - slovenčina" class="sk on" href="/doceo/document/CRE-7-2013-02-06-ITM-008-03_SK.html">sk - slovenčina</a></li>
            <li><a title="sl - slovenščina" class="sl on" href="/doceo/document/CRE-7-2013-02-06-ITM-008-03_SL.html">sl - slovenščina</a></li>
            <li><a title="fi - suomi" class="fi on" href="/doceo/document/CRE-7-2013-02-06-ITM-008-03_FI.html">fi - suomi</a></li>
            <li><a title="sv - svenska" class="sv on" href="/doceo/document/CRE-7-2013-02-06-ITM-008-03_SV.html">sv - svenska</a></li>
        </ul></div></td></tr><tr><td style="padding:10px;"><table width="100%" border="0" cellspacing="0" cellpadding="0"><tr><td><table border="0" align="left" cellpadding="0" cellspacing="0"><tr><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-7-2013-02-06-TOC_EN.html"><img src="/doceo/data/img/navi_index.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-7-2013-02-06-TOC_EN.html" title="Index">Index</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-7-2013-02-06-ITM-008-02_EN.html"><img src="/doceo/data/img/navi_previous.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-7-2013-02-06-ITM-008-02_EN.html" title="Previous">Previous</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td valign="middle"> <a href="/doceo/document/CRE-7-2013-02-06-ITM-008-04_EN.html" title="Next">Next</a> </td><td><a href="/doceo/document/CRE-7-2013-02-06-ITM-008-04_EN.html"><img src="/doceo/data/img/navi_next.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-7-2013-02-06_EN.html"><img src="/doceo/data/img/navi_moredetails.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-7-2013-02-06_EN.html" title="Full text">Full text</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td></tr><tr><td><img src="/doceo/data/img/spacer.gif" width="10" height="15" alt="" /></td></tr></table></td></tr></table>
                <table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td align="left"><span class="contents">Procedure : </span><a class="ring_ref_link" href="https://oeil.secure.europarl.europa.eu/oeil/popups/ficheprocedure.do?lang=en&amp;reference=2012/0035(COD)">2012/0035(COD)</a></td><td align="right"><table align="right" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td><img src="/doceo/data/img/ring_tabs_left_doc_unselected.gif" height="19" width="4" alt="" /></td><td class="Tabs_doc_unselected"><img src="/doceo/data/img/ring_navi.gif" width="17" height="14" alt="" />Document stages in plenary</td><td valign="middle"><img src="/doceo/data/img/ring_tabs_right_doc_unselected.gif" height="19" width="4" alt="" /></td></tr></tbody></table></td></tr></tbody></table><table class="doc_box_header" border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="ring_multiple_bg" valign="top" colspan="7">Document selected :
            <span class="ring_ref_selected_header">A7-0015/2013</span></td></tr><tr><td width="25%" valign="top" class="ring_step_bg1" nowrap="nowrap"><p class="ring_step_title">Texts tabled :</p>
                        <a href="/doceo/document/A-7-2013-0015_EN.html" class="ring_ref_link">A7-0015/2013</a><br />
                    </td><td width="15" style="background-image:url(/doceo/data/img/ring_bg1.gif)"><img src="/doceo/data/img/ring_flech1.gif" height="22" width="13" border="0" alt="" /></td><td class="ring_step_bg2" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Debates :</p>
                        <a href="/doceo/document/PV-7-2013-02-04-ITM-020_EN.html" class="ring_ref_link">PV 04/02/2013 - 20</a><br />
                        <a href="/doceo/document/CRE-7-2013-02-04-ITM-020_EN.html" class="ring_ref_link">CRE 04/02/2013 - 20</a><br />
                    </td><td width="15" style="background-image:url(/doceo/data/img/ring_bg2.gif)"><img src="/doceo/data/img/ring_flech2.gif" width="13" height="22" border="0" alt="" /></td><td class="ring_step_bg3" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Votes :</p>
                        <a href="/doceo/document/PV-7-2013-02-06-ITM-005-03_EN.html" class="ring_ref_link">PV 06/02/2013 - 5.3</a><br />
                        <a href="/doceo/document/CRE-7-2013-02-06-ITM-005-03_EN.html" class="ring_ref_link">CRE 06/02/2013 - 5.3</a><br />
                        <a class="ring_ref_selected">Explanations of votes</a><br />
                    </td><td width="19" style="background-image:url(/doceo/data/img/ring_bg3.gif)"><img src="/doceo/data/img/ring_flech3.gif" height="22" width="13" border="0" alt="" /></td><td class="ring_step_bg4" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Texts adopted :</p>
                        <a href="/doceo/document/TA-7-2013-0039_EN.html" class="ring_ref_link">P7_TA(2013)0039</a><br />
                    </td></tr></tbody></table><br />
            <table width="100%" border="0" cellpadding="5" cellspacing="0" class="doc_box_header">
<tr>
<td align="left" valign="top" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="title_TA">Verbatim report of proceedings</td><td valign="top" align="right" style="background-image:url(/doceo/data/img/gradient_blue.gif)"></td>
</tr>
<tr>
<td class="doc_title" align="left" valign="top" bgcolor="#F5F5F5">Wednesday, 6 February 2013 - Strasbourg</td>
<td class="doc_title" align="right" valign="top" bgcolor="#F5F5F5">Revised edition</td></tr></table><br />
<table width="100%" border="0" cellpadding="0" cellspacing="0" class="doc_box_header" style="padding-bottom:5px"><tr valign="top"><td>
<table width="100%" border="0" cellpadding="5" cellspacing="0"><tr valign="top" style="padding-bottom:0px;padding-left:5px;padding-right:5px;padding-top:5px"><td align="left" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="doc_title"><img src="/doceo/data/img/arrow_title_doc.gif" width="8" height="14" border="0" align="absmiddle" alt="" /> 8.3. Transparency of measures regulating the prices of medicinal products for human use (<a href="/doceo/document/A-7-2013-0015_EN.html">A7-0015/2013</a> - Antonyia Parvanova) </td><td style="background-image:url(/doceo/data/img/gradient_blue.gif)" width="10"><table cellSpacing="0" cellPadding="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20130206-13:55:44&amp;playerEndTime=20130206-14:06:21" target="_blank"><img width="29" height="20" src="/doceo/data/img/vod_all_speakers_left.gif" border="0" /></a></td><td class="switch_button_pv_cre"><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20130206-13:55:44&amp;playerEndTime=20130206-14:06:21" target="_blank">Video of the speeches</a></td><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20130206-13:55:44&amp;playerEndTime=20130206-14:06:21" target="_blank"><img width="5" height="20" src="/doceo/data/img/switch_pv_cre_right.gif" border="0" /></a></td></tr></table></td></tr></table>
<a name="3-188-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><span class="bold">Προφορικές αιτιολογήσεις ψήφου</span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-189-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96944.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20130206-13:55:56&amp;playerEndTime=20130206-13:56:53" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marina Yannakoudakis (ECR). - </span></span>  Madam President, I believe in a single market for medicinal products. In order for this market to function properly, we need a level playing field and greater transparency, and this means that pricing and reimbursement of medicines must be based on objective and verifiable criteria. However, Member States have exclusive competence in deciding on the pricing and reimbursement of medicines. Therefore, we must ensure that the new directive does not interfere with national competences. </p>
<p class="contents">I voted for this report because I believe that, unlike the original Commission proposal, it offers a good deal for patients. It sets out faster and clearer procedural rules for pricing medicinal products. I hope the Commission will use the report as a basis for a new proposal that will ensure the effectiveness of the system.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-190-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/41007.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20130206-13:56:59&amp;playerEndTime=20130206-13:57:54" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Iva Zanicchi (PPE). - </span></span>  Signora Presidente, onorevoli colleghi, i dubbi troppo spesso legati alla fissazione del prezzo e alle modalità di rimborso dei prodotti farmaceutici hanno reso necessario aggiornare il quadro normativo in vigore nel rispetto della competenza esclusiva degli Stati membri. Nel decidere riguardo ai prezzi e al rimborso dei medicinali diviene quindi fondamentale promuovere la produzione di farmaci a costi accessibili, abolire gli ostacoli relativi al commercio dei medicinali generici e incoraggiare la ricerca e lo sviluppo per garantire cure a prezzi sostenibili per i cittadini europei.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-191-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28117.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20130206-13:57:52&amp;playerEndTime=20130206-13:58:56" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Jim Higgins (PPE). - </span></span>  Madam President, I would like to thank the rapporteur and the shadows for the work they have done on this important issue. It is absolutely vital that we work to create greater transparency of the measures regulating the price of the medical products. It is also very important that we do this now, as the directive in effect is completely outdated. </p>
<p class="contents">The conditions present in the pharmaceutical markets are vastly different to the ones which existed when the previous directives were put in place. More medical products are now available thanks to medical advances and generic medicines. They are now more readily available to the consumer and they are cheaper.</p>
<p class="contents">Furthermore, the directive in force, which dates from the 1980s, must be replaced. Otherwise it will be increasingly challenging for the Member States to implement it. We have adopted an excellent measure today; the time limits laid down by the previous directive are not feasible in the modern day. So it is a good day’s work.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-192-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96824.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20130206-13:58:57&amp;playerEndTime=20130206-14:00:12" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Monica Luisa Macovei (PPE). -</span></span>   Madam President, transparency opens the way to integrity and accountability, and we need greater transparency in the decision-making process for the pricing and reimbursement of pharmaceutical products.</p>
<p class="contents">The pricing and reimbursement of pharmaceutical products fall within the Member States’ exclusive competence. However, we need minimum procedural requirements in order to ensure the proper functioning of the single market, as well as legal certainty and transparency for national authorities. </p>
<p class="contents">The names and declarations of interests of the experts involved in the decision-making process should be disclosed – they should be published and made available. Moreover, the public should be aware of and have access to all the documents and information relating to a given decision. Greater transparency is the key to assessing the level of integrity and independence of decisions taken and to reinforcing citizens’ trust and confidence in their national health authorities.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-193-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28422.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20130206-14:00:13&amp;playerEndTime=20130206-14:01:34" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Alfredo Antoniozzi (PPE). - </span></span>  Signora Presidente, onorevoli colleghi, il testo proposto dalla Commissione era frutto di un'analisi accurata delle attuali condizioni dei mercati farmaceutici, nonché dell'attuale contesto e dei vincoli finanziari cui le autorità competenti sono soggette in materia di decisione sulla fissazione del prezzo e sul rimborso dei medicinali.</p>
<p class="contents">Condivido in pieno l'opinione secondo cui l'obiettivo generale di tale proposta dovrebbe essere quello di aggiornare il quadro legislativo esistente in modo da chiarire gli obblighi procedurali per gli Stati membri e garantire il buon funzionamento del mercato unico e l'efficacia della legislazione in materia di mercato interno.</p>
<p class="contents">Vi erano grandi ritardi nelle decisioni in materia di fissazione dei prezzi e di rimborso e credo che con le soluzioni adottate riusciremo finalmente a porvi un rimedio. Devo prendere atto che la competenza esclusiva degli Stati membri in questa materia è stata rispettata. I requisiti procedurali minimi dovrebbero garantire certezze giuridiche e trasparenza per le autorità nazionali competenti. Promuovere quindi la produzione di medicinali e l'entrata sul mercato dei medicinali generici.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-194-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/4521.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20130206-14:01:36&amp;playerEndTime=20130206-14:02:40" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Charles Tannock (ECR). -</span></span>   Madam President, 20 years ago there were only 12 Member States and the single market was only a few months old. Despite all the fundamental changes that have occurred since then, the existing directive regulating the pricing of pharmaceutical products has not once been amended. It is therefore absolutely necessary to update this directive in the interests of patients and health insurance providers. </p>
<p class="contents">While the transparency directive will encourage greater efficiency, efficiency does not translate automatically into hastiness, which is why I welcome the compromises on time limits. Above all this legislation, which I voted for, could offer an exemplary reconciliation of Member State competence and Single Market harmonisation, giving patients faster and more cost-effective access to medicines while ensuring that their prices are fairly administered within the limits of national rules and regulations.</p>
<p class="contents">Let me also put on the record that I am proud that the European Medicines Agency is based in my London constituency – a rare example of an EU agency which provides good value for money.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-195-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96951.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20130206-14:02:42&amp;playerEndTime=20130206-14:03:45" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Diane Dodds (NI). - </span></span>  Madam President, I share the committee’s desire to see vital EU medicinal products reach those who need them most in the fastest possible time. As in other regions, people living in my constituency in Northern Ireland should have access to the most successful and specialised medicines available. It is therefore necessary to reduce administrative barriers to trade. </p>
<p class="contents">A balance must be found, however, between making the national procedures that set prices for pharmaceuticals more efficient and ensuring that products are judged solely on how effective they will be in meeting health demands. I support the plans to reduce the time limits for decisions on pricing and reimbursements for generic medicines. I also welcome provisions which would compel decision-making bodies to make public the names of their expert members, as well as the reasons for their judgments.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-196-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/4555.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20130206-14:03:46&amp;playerEndTime=20130206-14:05:01" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Daniel Hannan (ECR). - </span></span>  Madam President, one of the most scandalous episodes I have lived through as a Member of the European Parliament was the banning and restriction of a number of higher-dose vitamin and mineral supplements and herbal remedies by their reclassification as pharmaceutical products. The justification was the precautionary principle, which is one of those ideas that sounds plausible but turns out to be specious. </p>
<p class="contents">In the 19<span class="sup">th </span>century it was widely believed that the noise of a passing train would cause miscarriages in pregnant women. Had we applied the precautionary principle we would not have laid a single inch of track, because the rail operators at that time could no more prove that they would not cause miscarriages than the herbalist can prove that her products are not deleterious to health. There is such a thing as ‘benefit of the doubt’. It is not a good business model to go around poisoning your customers and opening yourself to massive liabilities.</p>
<p class="contents">Of course the real reason that these restrictions were brought in was because a handful of massive pharmaceutical corporations which could easily afford the compliance costs saw it as an opportunity to put their smaller competitors out of business, which is exactly what has happened. Once again, we see that consumers, taxpayers and entrepreneurs are disadvantaged in favour of the handful of corporate interests which are the real beneficiaries of this system.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-197-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28316.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20130206-14:05:10&amp;playerEndTime=20130206-14:06:14" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Hannu Takkula (ALDE). - </span></span>  Arvoisa puhemies, äänestin tämän mietinnön puolesta. On erittäin tärkeää, että lääkkeet voivat olla kohtuuhintaisia Euroopan unionin kansalaisille. Tärkeää on myös muistaa se, että lääketeollisuudessa tutkimustyötä tekevien työ pitää ottaa huomioon sen sijaan että olisi hyvin lyhyet suoja-ajat ja sen jälkeen jotkut voivat kopioida lääkkeitä.</p>
<p class="contents">Tärkeintä on huolehtia siitä, että myös lääketieteellinen tutkimus ja lääkkeiden kehittäminen menevät eteenpäin voimakkaasti ja että niitä rahoitetaan. Monissa maissa on omat järjestelmänsä tehdä tämä erilaisten tutkimusohjelmien kautta, ja myös kalliimpia lääkkeitä sairausvakuutusjärjestelmän kautta korvataan kansalaisille. Lähtökohtaisesti on erittäin hyvä, että me saamme laadukkaita lääkkeitä edullisesti, mutta on myös tärkeää huolehtia siitä, että lääkkeitä voidaan kehittää jatkuvasti ja sitä kautta satsataan lääketeollisuuteen ja sen innovaatioihin.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-198-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20130206-14:06:12&amp;playerEndTime=20130206-14:06:23" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><span class="bold">Γραπτές αιτιολογήσεις ψήφου</span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-198-250"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96976.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Luís Paulo Alves (S&amp;D), </span></span>  <span class="italic">por escrito</span>. <span class="bold">−</span> Acolho favoravelmente a proposta da Comissão e as respetivas disposições principais, no contexto das limitações atuais, nomeadamente financeiras, ao abrigo das quais as autoridades competentes têm de deliberar sobre a fixação de preços e reembolsos dos medicamentos. Considero que o objetivo geral da presente proposta deve ser a atualização do quadro legislativo existente, a fim de clarificar e de assegurar o bom funcionamento do Mercado Único e a eficácia da legislação relativa ao mercado interno, nas decisões sobre a fixação de preços e reembolsos e de obstáculos ao comércio de produtos farmacêuticos. Como prioridade, gostaria de insistir na necessidade de reforçar as disposições relacionadas com a transparência do processo de tomada de decisões e com as decisões tomadas, que representa uma crescente exigência da sociedade. Por conseguinte, sugiro um conjunto de medidas adicionais, particularmente a obrigação das autoridades competentes de divulgar os nomes e as declarações de interesses dos peritos que sejam membros dos órgãos de decisão das autoridades competentes. Essas disposições, bem como um aumento da disponibilização ao público de documentos e informações, visam reforçar a transparência, integridade e independência das decisões tomadas e devem, em última análise, reforçar a confiança nas autoridades públicas responsáveis a nível nacional.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-198-375"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28276.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Laima Liucija Andrikienė (PPE), </span></span>  <span class="italic">raštu</span><span class="bold">. −</span> Balsavau už šią rezoliuciją dėl vaistų kainų skaidrumo. Europos Parlamentas pritarė Komisijos pasiūlymui atnaujinti esamą teisės aktų sistemą siekiant patikslinti valstybių narių procedūrines prievoles ir užtikrinti vidaus rinkos teisės aktų efektyvumą tiek siekiant išvengti vilkinimo priimant sprendimus dėl kainų nustatymo ir kompensavimo, tiek šalinant prekybos farmacijos produktais kliūtis. Be abejonės, išskirtinė valstybių narių kompetencija priimant sprendimus dėl vaistų kainų ir jų kompensavimo turi būti gerbiama, tačiau taip pat turėtų būti minimaliais procedūriniais reikalavimais užtikrinamas teisinis tikrumas ir skaidrumas nacionalinėms kompetentingoms institucijoms, skatinama vaistų gamyba ir generinių vaistų patekimas į rinką ir skatinami moksliniai tyrimai ir naujų vaistų kūrimas. Tai sudarytų sąlygas visiems Europos pacientams gauti prieinamą gydymą ir geresnius bei pigesnius vaistus.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-198-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96862.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Sophie Auconie (PPE), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> Le Parlement européen a voté en faveur de la révision de la directive de 1989 sur la transparence des procédures de fixation du prix des médicaments. Ce texte introduit de nouveaux éléments pour faciliter une mise en œuvre effective et pratique des délais. L’objectif est qu’un cadre commun réaliste puisse être respecté au sein de l’Union quant aux délais de fixation pour le prix et le remboursement des médicaments tout en renforçant la transparence. J’ai donc également voté en faveur de ce rapport.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-199-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28114.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Liam Aylward (ALDE), </span></span>  <span class="italic">i scríbhinn</span><span class="bold">. − </span>Is cinnte gur chóir inniúlacht na mBallstát maidir le praghsáil agus aisíocaíochtaí táirgí íocshláinte a chosaint ach ní foláir freisin go ndéanfaimis iarracht cóir leighis ar phraghas réasúnta a chur ar fáil do gach uile dhuine san AE. Fearaim fáilte roimh an moladh i dtaca le tréimhsí feithimh níos gaire a chur i bhfeidhm do dhrugaí cineálacha, a bheadh chun leasa tomhaltóirí agus córais sláinte phoiblí, agus tacaím go hiomlán le hiarratas an Rapóirtéara maidir le trédhearcacht na gcóras praghsála agus aisíocaíochta do tháirgí cógaisíochta a fheabhsú. Cé go bhfuil laghdú tagtha ara bhfuil á íoc in Éirinn ar dhrugaí ar oideas, tá an chosúlacht ar an scéal go bhfuil tomhaltóirí agus cáiníocóirí Éireannacha ag íoc dhá oiread agus atá á íoc sa Fhrainc, sa Spáinn agus sa Bhreatain. Aontaím gur chóir go mbeadh solúbthacht ann do na Ballstáit an Treoir seo a chur i bhfeidhm de réir a rialacháin féin ach ní foláir go mbeadh na húdaráis náisiúnta ag tabhairt aghaidhe ar dhifríochtaí i bpraghas ó thír go tír agus ag cinntiú go bhfuil teacht ag daoine ar chóir leighis ar phraghas réasúnta agus nach bhfuil sailleadh á déanamh ar na Ballstáit agus táirgí íocshláinte á gceannach.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-199-062"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96680.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Zigmantas Balčytis (S&amp;D), </span></span>  <span class="italic">raštu</span><span class="bold">. −</span> Balsavau už šį siūlymą dėl priemonių, reglamentuojančių žmonėms skirtų vaistų kainas, skaidrumo. Šio siūlymo tikslas – paspartinti generinių vaistų išleidimą į rinką supaprastinant nacionalinių sprendimų dėl vaistų kainos tvarką ir sutrumpinant šių sprendimų priėmimo laiką. Generiniai vaistai – tai pigesni esamų vaistų analogai, pardavinėjami pasibaigus patento galiojimui. Komisijos duomenimis tokie vaistai, net 40 % pigesni negu originalūs, todėl patentą turinčios įmonės siekia kuo ilgiau pratęsti savo išskirtinę teisę pardavinėti originalus, neįleisdamos į rinką jų analogų. Labai svarbu tai pakeisti ir sudaryti sąlygas ES piliečiams įsigyti pigesnių vaistų. Numatoma nustatyti 60 dienų laikotarpį sprendimui dėl generinių vaistų kainos ir kompensavimo tvarkos priėmimo (šiandien toks sprendimas gali trukti net iki 700 dienų). Pritariu šiam siūlymui bei siūlymui nustatyti prievolę vaistų kontrolės tarnyboms atskleisti savo ekspertų, priimančių sprendimus dėl vaistų kainų ir kompensavimo, pavardes ir interesų deklaracijas bei siūlymui kartą per metus viešai skelbti kompensuojamų vaistų ir jų kainų sąrašus.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-199-125"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/5956.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Regina Bastos (PPE), </span></span>  <span class="italic">por escrito</span>. <span class="bold">−</span> O presente relatório prevê uma atualização abrangente da Diretiva 89/105/CEE, com o objetivo de garantir a transparência das medidas nacionais que regulamentam a formação dos preços dos medicamentos para uso humano e a sua inclusão nos sistemas nacionais de seguro de saúde. As disposições da Diretiva em questão refletem as condições que vigoravam no mercado farmacêutico há mais de vinte anos e que sofreram, desde então, profundas alterações. Exemplo disso, é o aparecimento de medicamentos genéricos que oferecem alternativas mais baratas aos medicamentos de marca ou do desenvolvimento de medicamentos baseados na investigação cada vez mais inovadores. Neste sentido, torna-se necessário reforçar as disposições relacionadas com a transparência do processo de tomada de decisões e com as decisões tomadas e obrigar as autoridades competentes a divulgar os nomes e declarações de interesses dos peritos que sejam membros dos órgãos de decisão. Os procedimentos de recurso em caso de incumprimento dos prazos relativos à inclusão dos medicamentos nos sistemas nacionais de seguros de saúde deve permanecer administrativo e, em caso de atrasos injustificados, ser reencaminhado para a instância administrativa ou jurídica relevante de acordo com a legislação nacional. Pelo exposto, apoiei o presente relatório.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-199-250"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96947.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Nora Berra (PPE), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> J'accorde ma voix en faveur du rapport d'Antonyia Parvanova qui partage l'avis selon lequel l'objectif global de la proposition est de mettre à jour le cadre législatif en vigueur afin de clarifier les obligations procédurales qui incombent aux États membres et de garantir le bon fonctionnement du marché unique.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-199-375"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/97198.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Mara Bizzotto (EFD), </span></span>  <span class="italic">per iscritto</span><span class="bold">. −</span> Ho sostenuto col mio voto la relazione Paranova, sulla proposta della Commissione che intende sostituire la direttiva 89/105/CEE riguardante la trasparenza delle misure che disciplinano la fissazione dei prezzi dei medicinali per uso umano e la loro inclusione nei regimi nazionali di assicurazione malattia. Le modifiche saranno apportate al fine di adeguare i contenuti attuali secondo requisiti di maggiore trasparenza da applicarsi a tutte le misure di fissazione dei prezzi e di rimborso. Le nuove disposizioni terranno conto della giurisprudenza della Corte di Giustizia e saranno affiancate da nuovi strumenti atti a facilitare il dialogo con gli Stati membri.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-199-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96681.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Vilija Blinkevičiūtė (S&amp;D), </span></span>  <span class="italic">raštu</span><span class="bold">. −</span> Balsavau už šį pranešimą, kadangi yra svarbu užtikrinti vaistų gamybą ir generinių vaistų patekimą į rinką. Be to, reikėtų skatinti mokslinius tyrimus ir naujų vaistų kūrimą, siekiant pagerinti visų Europos pacientų galimybes gauti prieinamą gydymą. Svarbu pažymėti, jog, nors ir valstybės narės yra atsakingos už savo sveikatos priežiūros sistemų, sveikatos paslaugų ir sveikatos priežiūros organizavimą, kiekviena valstybė narė gali imtis priemonių vaistų vartojimui valdyti, kainoms reguliuoti arba viešojo finansavimo sąlygoms nustatyti. Todėl šiuo Komisijos pasiūlymu yra siekiama susisteminti minimalius reikalavimus, siekiant užtikrinti, kad nacionalinės priemonės, visų pirma tos, pagal kurias reglamentuojamas žmonėms skirtų vaistų kainų nustatymas ir kompensavimas, neprieštarautų laisvo prekių judėjimo principui. Šiuo tikslu nagrinėjamoje direktyvoje nustatyta keletas procedūrinių reikalavimų, skirtų valstybių narių priimtų kainų nustatymo ir kompensavimo priemonių skaidrumui užtikrinti, įskaitant atitinkamų sprendimų priėmimo terminus ar prievolę. Trumpiau tariant, tuo tikslu, kad kompetentingos nacionalinės institucijos nurodytų kiekvieno savo sprendimo motyvus ir užtikrintų paraiškas pateikusioms bendrovėms atitinkamas teisių gynimo priemones. Šie pasiūlymai turėtų prisidėti prie veiksmingos ir saugios sveikatos srities politikos, kuri būtų orientuota į pacientus ir kuria būtų siekiama užtikrinti geriausią kainos ir kokybės santykį.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-200-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/39722.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Sebastian Valentin Bodu (PPE), </span></span>  <span class="italic">în scris</span><span class="bold">. −</span> Tratatul privind funcţionarea Uniunii Europene prevede că statelor membre le revine sarcina să îşi organizeze sistemele proprii de sănătate şi să presteze servicii de sănătate şi de îngrijire medicală. În acest cadru, fiecare stat membru poate să adopte măsuri de gestionare a consumului de medicamente, să reglementeze preţurile acestora sau să stabilească condiţiile de finanţare publică a acestora. Astfel, un medicament autorizat în conformitate cu legislaţia UE pe baza profilului calităţii, siguranţei şi eficacităţii sale poate face obiectul unor cerinţe de reglementare suplimentare la nivel de stat membru, înainte de a fi introdus pe piaţă sau eliberat pacienţilor în cadrul sistemului public de asigurări de sănătate. Faţă de cele mai sus menţionate, consider că existenţa unor cerinţe minime procedurale ar trebui să garanteze siguranţă juridică şi transparenţă pentru autorităţile naţionale competente şi să promoveze producerea de medicamente şi intrarea pe piaţă a medicamentelor generice. Este necesar să se încurajeze cercetarea şi dezvoltarea unor medicamente noi pentru a facilita accesul tuturor pacienţilor din Europa la tratamente abordabile.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-200-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96798.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">John Bufton (EFD), </span></span>  <span class="italic">in writing</span><span class="bold">. −</span> I voted against this report as I am wholly opposed to the EU regulating our medicine, and in particular the pricing of our medicine, in the UK.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-200-625"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96867.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Maria Da Graça Carvalho (PPE), </span></span>  <span class="italic">por escrito</span>. <span class="bold">−</span> Concordo de formal geral com o presente relatório que apoia a proposta da Comissão Europeia face à atualização do quadro legislativo existente em matéria de fixação do preço e transparência dos medicamentos para uso humano, de forma a garantir o bom funcionamento do Mercado Único e a eficácia da legislação em vigor. Será importante garantir que a lei abre espaço para que seja promovida a introdução no mercado de medicamentos genéricos, incentivar a investigação e o desenvolvimento de novos medicamentos, facilitando o acesso a tratamentos financeiramente acessíveis a todos os doentes da Europa. A garantia de transparência do processo de tomada de decisões é fundamental, de forma muito vincada no que toca à fixação de preços, pois reforça a confiança nas entidades responsáveis. O presente relatório propõe ainda que a proposta da Comissão seja alterada, a fim de garantir uma execução prática e eficaz das disposições previstas e conferir às autoridades nacionais competentes o nível necessário de flexibilidade e autonomia para cumprir os requisitos da presente diretiva. O princípio da proporcionalidade deve também ser garantido. Esta proposta é positiva sendo mais uma alavanca na garantia de políticas de saúde seguras e eficazes, centradas no doente e na geração de valor. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-200-750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28148.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Françoise Castex (S&amp;D), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> Le Parlement européen s’est exprimé aujourd’hui sur la révision de la directive de 1989 sur la fixation du prix des médicaments. Ce texte prévoit les procédures à respecter pour définir le prix de vente et les conditions de remboursement des médicaments. Le point le plus contesté était l'introduction de nouveaux délais de traitement des demandes considérablement raccourcis, irréalistes, et assortis d'une clause d'acceptation tacite du prix demandé par le laboratoire an cas de non-respect des délais. Une telle mesure n'est ni proportionnée, ni conforme au principe de subsidiarité! Nous avons pu allonger les délais, ce qui rend le texte acceptable, en revanche, la clause d'acceptation tacite n'a été supprimée que pour les demandes d'augmentation de prix, ce qui est regrettable, même si l'essentiel est que les autorités disposent du temps nécessaire.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-201-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/26851.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Νικόλαος Χουντής (GUE/NGL), </span></span>  <span class="italic">γραπτώς</span><span class="bold">. –</span> Καταψήφισα την έκθεση Parvanova παρά τις βελτιώσεις που επέφερε σε ορισμένα σημεία στην απαράδεκτη πρόταση οδηγίας της Ευρωπαϊκής Επιτροπής. Θεωρώ ιδιαίτερα προβληματικά τα ακόλουθα σημεία : 1. Δυστυχώς η Ολομέλεια σήμερα απέρριψε τη διπλή νομική βάση ( άρθρα 114 και 168) κρατώντας μόνο το 114 και υπονομεύοντας με τον τρόπο αυτό την ευθύνη των κρατών μελών για τα εθνικά συστήματα ασφάλισης υγείας που σύμφωνα με το άρθρο 168 εμπίπτει τις ευθύνες τους. 2. Η Ευρωπαϊκή Επιτροπή επιβάλλει κυρώσεις σε περίπτωση μη τήρησης των προθεσμιών για την επιστροφή δαπανών. Κάτι τέτοιο αντίκειται στην αρχή της επικουρικότητας και θέτει μεγάλο πρόβλημα στα ασφαλιστικά ταμεία. Υπονομεύει την ικανότητα των αρχών τιμολόγησης και επιστροφής δαπανών να ανταποκριθούν στην αποστολή τους για την προστασία της δημόσιας υγείας και προσθέτει περιττά διοικητικά και οικονομικά βάρη στα συστήματα δημόσιας υγείας που θα θέσουν σε κίνδυνο τη βιωσιμότητά τους και την πρόσβαση των ασθενών σε ασφαλή φάρμακα. 3. Απαγορεύεται στα κράτη μέλη, στο πλαίσιο των αποφάσεων τιμολόγησης και επιστροφής δαπανών, να επαναξιολογήσουν τα στοιχεία στα οποία βασίστηκε η άδεια κυκλοφορίας, συμπεριλαμβανομένων της αποτελεσματικότητας, της ποιότητας ή της ασφάλειας του φαρμάκου. Δυστυχώς οι τροπολογίες που κατέθεσε η ομάδα μου για να εξαλείψει αυτές τις διατάξεις απορρίφθηκαν.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-202-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/113597.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Minodora Cliveti (S&amp;D), </span></span>  <span class="italic">în scris</span><span class="bold">. −</span> Principalul beneficiar al sistemului medical trebuie să fie şi să rămână pacientul. Uniunea Europeană trebuie să promoveze o politică transparentă, predictibilă şi coerentă a sistemului sanitar care să garanteze tuturor pacienţilor europeni un acces în timp real, eficient şi de calitate atât la medicamentele originale, cât şi la cele generice. Complexitatea şi diversitatea măsurilor naţionale legate de stabilirea preţurilor medicamentelor a crescut considerabil după 1989, de la adoptarea Directivei 89/105/CEE privind transparenţa pentru produsele farmaceutice. Comisia Europeană a propus dispoziţii fundamentale de actualizare a cadrului legislativ actual pentru a clarifica obligaţiile procedurale care revin statelor membre şi pentru a asigura buna funcţionare a pieţei unice şi eficienţa legislaţiei privind piaţa internă, atât prin evitarea întârzierilor în ceea ce privește stabilirea preţurilor şi deciziile de rambursare, cât şi prin înlăturarea obstacolelor din calea comerţului de produse farmaceutice. Avem nevoie de decizii mai rapide privind stabilirea preţurilor şi rambursarea pentru a menţine dinamismul pieţei farmaceutice şi pentru a oferi cetăţenilor un acces mai bun la medicamente. De asemenea, facilitarea intrării mai rapide pe piaţă a medicamentelor generice are o deosebită importanţă pentru promovarea unui sistem sanitar coerent şi cu o mai mare transparenţă şi va conduce la economii substanţiale atât pentru bugetele alocate sănătăţii publice, cât şi pentru pacienţi.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-203-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/1892.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Carlos Coelho (PPE), </span></span>  <span class="italic">por escrito</span>. <span class="bold">−</span> Recai sobre os Estados-Membros a responsabilidade de organizarem os respetivos sistemas de saúde, a prestação de serviços e cuidados médicos e a repartição dos recursos que lhe são afetados, mas deverão sempre fazê-lo no pleno respeito das condições mínimas estabelecidas ao nível da UE, em termos de qualidade, segurança e eficácia dos medicamentos, mas também de forma a garantir a sua compatibilidade com as regras do mercado interno e o princípio da livre circulação de mercadorias.</p>
<p class="contents">A Diretiva que estabelece os requisitos mínimos de forma a garantir a transparência das medidas de fixação de preços e reembolsos adotadas pelos Estados-Membros deixou de estar adequada às condições atuais dos mercados farmacêuticos. Apoio esta atualização do quadro legislativo vigente, introduzindo uma maior transparência e segurança jurídica. Estes requisitos processuais mínimos deverão contribuir para promover a produção de medicamentos, a introdução no mercado de medicamentos genéricos e incentivar a investigação e o desenvolvimento de novos medicamentos, facilitando o acesso a tratamentos financeiramente acessíveis a todos os doentes da Europa. Acredito que as exigências propostas, de forma a garantir decisões atempadas e transparentes, asseguram o equilíbrio necessário entre a obrigação de preservar as competências dos Estados-Membros no domínio da saúde pública e a necessidade de garantir a eficácia da Diretiva no âmbito do mercado interno.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-203-250"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/33997.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Corina Creţu (S&amp;D), </span></span>  <span class="italic">în scris</span><span class="bold">. −</span> Susţin această rezoluţie pentru că este vital să sprijinim creşterea raportului cost-eficienţă în ceea ce priveşte produsele farmaceutice. În vederea asigurării bunei funcţionări a pieţei unice, a facilitării accesului pacienţilor la rambursări în cadrul sistemelor publice de asigurări de sănătate şi pentru a încuraja schimbul comercial al acestor produse farmaceutice, avem nevoie de un cadru juridic transparent şi de un sistem transparent şi armonizat de reglementare a preţurilor.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-203-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/95281.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Vasilica Viorica Dăncilă (S&amp;D), </span></span>  <span class="italic">în scris</span><span class="bold">. −</span> Consider că inovarea şi cercetarea în domeniul sănătăţii aduc avantaje semnificative pentru pacienţi şi are consecinţe pozitive asupra eficacităţii şi durabilităţii sistemelor de sănătate.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-203-625"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/4335.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marielle de Sarnez (ALDE), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> Si l’Union européenne dispose d'un marché uniformisé en matière de libre circulation des travailleurs, des biens et des capitaux, il existe toujours d'énormes différences entre États membres, s'agissant du fonctionnement des systèmes de santé et de remboursement des médicaments, politiques qui relèvent des États membres. Par exemple, des médicaments sont aujourd'hui remboursés après 700 jours dans certains États. Sans empiéter sur ces compétences exclusives des Etats en matière de fixation des prix et de remboursement des médicaments, il apparaît nécessaire de prévoir des règles minimales permettant d’encourager la production de médicaments, l'entrée sur le marché de médicaments génériques et d’encourager la recherche et le développement de nouveaux médicaments afin de rendre les traitements médicaux abordables pour l’ensemble des citoyens européens.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-200-875"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96914.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Anne Delvaux (PPE), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> Je me réjouis du vote de ce rapport qui devrait permettre aux patients européens d'accéder plus rapidement à des médicaments génériques. Nous proposons aussi un délai de 60 jours pour décider du prix et du remboursement des médicaments génériques, en vue d'accélérer la disponibilité de ces produits et d'économiser l'argent des patients et des systèmes de sécurité sociale. Les autorités compétentes dans les États membres seraient également tenues de publier, au minimum une fois par an, une liste des médicaments couverts par leur système public d'assurance-maladie avec leur prix, une information aux patients qui me semble indispensable.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-203-687"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28310.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Edite Estrela (S&amp;D), </span></span>  <span class="italic">por escrito</span>. <span class="bold">−</span> Votei favoravelmente o relatório relativo à "transparência das medidas que regulamentam os preços dos medicamentos para uso humano", porque inclui propostas que permitirão atualizar o quadro legislativo existente, a fim de conferir maior transparência e segurança jurídica, de incentivar a investigação e o desenvolvimento de novos medicamentos, bem como de facilitar o acesso a tratamentos financeiramente acessíveis a todos os doentes da Europa.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-203-750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/4550.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Jill Evans (Verts/ALE), </span></span>  <span class="italic">in writing</span><span class="bold">. −</span> I abstained in the vote on this report. The current directive on the pricing of medicines reflects the market conditions of twenty years ago. However, these conditions have changed with the rise of generic medicines on the one hand and of expensive innovative medicines on the other hand. Generic products are on average 40% cheaper than the branded medicines once they have been available for two years. Although the report recognises these problems, it does not go far enough and in abstaining I wanted to flag these problems. It is important that we address the situation correctly. In Wales prescriptions are free to patients but speeding up the availability of generic medicines could save substantial sums for the NHS.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-204-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/doceo/data/img/photo_generic.gif" align="right" width="50" height="63" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Göran Färm, Anna Hedh, Olle Ludvigsson, Jens Nilsson, Marita Ulvskog och Åsa Westlund (S&amp;D), </span></span>  <span class="italic">skriftlig</span><span class="bold">. −</span> Vi svenska socialdemokrater anser att transparensdirektivet gällande prissättning och ersättning av läkemedel är ett för kraftigt ingripande i något som är och bör vara medlemsstaternas angelägenhet. Vi finner det mycket problematiskt att den svenska modellen för beslutsprocessen gällande generiska läkemedel inte ryms inom den föreslagna tidsfristen. Därför valde vi att rösta emot förslaget i slutomröstningen.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-204-750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96977.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Diogo Feio (PPE), </span></span>  <span class="italic">por escrito</span>. <span class="bold">−</span> A Diretiva 89/105/CEE relativa à transparência das medidas que regulamentam a formação do preço dos medicamentos nunca foi revista, embora as condições de mercado e as políticas de saúde tenham sofrido alterações substanciais nos últimos 20 anos. Assim sendo, reconheço a pertinência desta revisão e atualização da legislação vigente, a qual mantém, e bem, o princípio da autonomia dos Estados na regulamentação da formação dos preços e condições de reembolso (comparticipação) de medicamentos. Porém, são introduzidas importantes alterações no que respeita à (i) adaptação dos prazos das decisões de fixação de preços e de reembolsos, à (ii) clarificação da relação dos procedimentos de fixação de preços e de reembolsos com os direitos de propriedade intelectual e o procedimento de autorização de introdução no mercado, e à (iii) instituição de determinados instrumentos para facilitar o diálogo e a aplicação da diretiva e para assegurar o seu cumprimento efetivo.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-204-875"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96899.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">José Manuel Fernandes (PPE), </span></span>  <span class="italic">por escrito</span>. <span class="bold">−</span> Este relatório acolhe, de uma forma geral, a proposta da Comissão e as disposições principais, com base numa análise exata das condições atuais dos mercados farmacêuticos, bem como do contexto e das limitações atuais, nomeadamente financeiras, ao abrigo das quais as autoridades competentes têm de deliberar sobre a fixação de preços e reembolsos dos medicamentos. Assim, está previsto que as decisões nacionais sobre o preço e o reembolso dos medicamentos genéricos possam ser tomadas no prazo de 60 dias. No caso dos novos medicamentos, o prazo será de 180 dias. Os estudos realizados mostraram que estas decisões podem, atualmente, demorar até 250 dias no caso dos medicamentos genéricos e até 700 dias no caso dos medicamentos inovadores. Esta proposta deverá conduzir a poupanças significativas para os orçamentos de saúde pública e criar um quadro mais previsível para as empresas farmacêuticas e, consequentemente, proporcionar aos cidadãos um melhor acesso a estes produtos. Este relatório vai de encontro a uma crescente exigência da sociedade, nomeadamente quando se trata da fixação de preços e reembolsos de produtos farmacêuticos.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-205-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96706.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">João Ferreira (GUE/NGL), </span></span>  <span class="italic">por escrito</span>. <span class="bold">−</span> Os Estados-Membros são responsáveis pela organização dos respetivos sistemas de saúde e pela repartição dos recursos que lhe são afetados, incluindo na área dos medicamentos. Assim é e assim deve continuar a ser. A proposta da relatora, no seguimento da proposta da Comissão Europeia, a pretexto da necessária transparência na fixação do preço dos medicamentos (que não contestamos) e dos desenvolvimentos ao nível do sector farmacêutico, com desenvolvimento de novos medicamentos, acaba por submeter os Estados-Membros e os interesses dos cidadãos aos interesses da indústria farmacêutica. Caso os prazos agora estabelecidos para os Estados-Membros decidirem sobre o preço e sobre o sistema de reembolso de cada medicamento não sejam cumpridos, a indústria farmacêutica tem, no limite, o poder de impor unilateralmente o seu preço aos Estados. A proposta implica ainda limitações, que consideramos graves, da soberania dos Estados-Membros, nos domínios da reavaliação da segurança, eficácia e qualidade dos medicamentos. O nosso grupo apresentou alterações ao relatório, visando salvaguardar as competências dos Estados-Membros e impedir as inaceitáveis penalizações que afetarão ainda mais os serviços públicos de saúde - alvo já de um insidioso processo de desmantelamento progressivo, às mãos das troicas, ocupante e colaboracionista. Estas alterações foram rejeitadas pela maioria. Assim sendo, obviamente votámos contra.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-205-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28126.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Christofer Fjellner (PPE), </span></span>  <span class="italic">skriftlig</span><span class="bold">. −</span> Transparensdirektivet har ur svensk synvinkel varit kontroversiellt. Framför allt har den svenska regeringen oroat sig för att direktivet ska försvåra för den svenska generika-reformen, eftersom tidsramarna för godkännandeprocesserna för generiska läkemedel var snävare i kommissionens förslag. Parlamentet utökade tidsgränserna till 30 plus 30 dagar, och Christofer Fjellner (M) lade ett ändringsförslag som mjukar upp formuleringen och skänker ökad flexibilitet för generiska preparat. Med dessa förbättringar av kommissionens förslag kunde moderaterna rösta för det förslag som låg inför kammaren.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-206-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/23868.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Monika Flašíková Beňová (S&amp;D), </span></span>  <span class="italic">písomne</span><span class="bold">. −</span> Právne predpisy Únie poskytujú harmonizovaný rámec pre povoľovanie liekov na humánne použitie. V súlade so smernicou Európskeho parlamentu a Rady 2001/83/ES zo 6. novembra 2001, ktorou sa ustanovuje zákonník Spoločenstva o humánnych liekoch, sa môžu lieky na trh Únie uvádzať až po získaní povolenia na uvedenie na trh vychádzajúceho z hodnotenia ich kvality, bezpečnosti a účinnosti. Členské štáty boli v ostatnom období konfrontované s neustálym rastom výdavkov na lieky, čo viedlo k zavedeniu čoraz komplexnejšej politiky riadenia spotreby liekov v rámci vnútroštátnych systémov zdravotného poistenia. Príslušné orgány členských štátov zaviedli hlavne celý rad opatrení s cieľom kontrolovať predpisovanie liekov, regulovať ich ceny a stanoviť podmienky ich verejného financovania. Tieto opatrenia sa zameriavajú najmä na podporu verejného zdravia zabezpečením primeranej dostupnosti liekov v rámci primeraných nákladov a zároveň majú zabezpečiť finančnú stabilitu systémov verejného zdravotného poistenia. Rozdiely medzi jednotlivými vnútroštátnymi opatreniami však môžu brzdiť alebo deformovať obchod s liekmi v Únii, narúšať hospodársku súťaž, a tak priamo ovplyvňovať fungovanie vnútorného trhu s liekmi. Myslím si, že je opodstatnené návrh Komisie zodpovedajúcim spôsobom zmeniť a doplniť s cieľom zaručiť praktické a účinné vykonávanie plánovaných ustanovení a poskytnúť príslušným vnútroštátnym orgánom potrebnú mieru flexibility a autonómie v záujme splnenia požiadaviek predmetnej smernice.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-206-250"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/1164.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Bruno Gollnisch (NI), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> Voilà un exemple parfait de l'Europe sociale! Alors que ce n'est absolument pas dans ses attributions, l'Union européenne va pouvoir limiter et encadrer les capacités des États à décider des prix des médicaments et de toute la politique sociale et de santé qui va avec. Avec un grand bénéficiaire: l'industrie pharmaceutique. Et de grands perdants: les patients et les systèmes de sécurité sociale!</p>
<p class="contents">Plusieurs États membres se sont inquiétés de cet abus de pouvoir et de la violation manifeste du principe de subsidiarité par ce texte. Il est dommage que tous les Parlements nationaux n'aient pas joué leur rôle de gardiens de ce principe. Et il est également dommage que la majorité de ce Parlement ait jugé bon de rejeter la base juridique qui reconnaît aux États la responsabilité de la gestion des services de santé et des ressources qui leur sont affectées, pour ne retenir que celle qui privilégie la libre circulation des marchandises. Tout un symbole!</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-206-312"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28117.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Jim Higgins (PPE), </span></span>  <span class="italic">in writing</span><span class="bold">. −</span> I voted in favour of this report as it will allow us to move towards ensuring that every European citizen has access to affordable medical treatment. The conditions present in the pharmaceutical market of today are vastly different to those which existed when Directive 89/105/EEC was enacted. With many medical advances having occurred and greater accessibility to generic medicines, citizens can now have much cheaper access to medical treatments. However, the time limits laid down by Directive 89/105/EEC are not working for our Member States and they are instead creating delays in the entry of new generic medicines to the market. Replacing this Directive will further facilitate the entry of such generic medicinal products to the single market and this can only benefit consumers and all European citizens by enabling them to have access to treatments which are more affordable, while also creating greater transparency in the measures regulating the prices of medicinal products.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-206-375"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/5565.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Brice Hortefeux (PPE), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> J'accorde un grand intérêt à la santé publique, qui est généralement une des préoccupations majeures des citoyens européens. Les scandales du Médiator et des pilules de troisième génération, plus récemment, ont aggravé le sentiment de méfiance de la part des citoyens à l'égard des autorités gouvernementales et des agences de contrôle jugées peu efficaces en matière de prévention des risques et peu réactives lors de la prise de décision. Les Etats membres et la Commission européenne doivent redoubler de vigilance afin de garantir un haut niveau de santé publique, mais ils doivent également encourager toutes les mesures et les initiatives qui permettent à la recherche pharmaceutique de proposer des médicaments innovants. La transparence des mesures qui régissent la fixation des prix des médicaments est également une mesure nécessaire, car elle évite les pratiques déloyales et facilite un accès rapide des patients à ces médicaments innovants. Tous les efforts des États membres pour raccourcir le délai d'admission au remboursement et de fixation des prix doivent donc être encouragés.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-206-437"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96693.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Juozas Imbrasas (EFD), </span></span>  <span class="italic">raštu</span><span class="bold">. −</span> Balsavau už šį pasiūlymą. Bendras šio pasiūlymo tikslas turėtų būti atnaujinti esamą teisės aktų sistemą siekiant patikslinti valstybių narių procedūrines prievoles ir užtikrinti bendros rinkos gerą veikimą bei vidaus rinkos teisės aktų efektyvumą tiek siekiant išvengti vilkinimo priimant sprendimus dėl kainų nustatymo ir kompensavimo, tiek šalinant prekybos farmacijos produktais kliūtis. Šios naujos taisyklės turėtų paspartinti generinių vaistų išleidimą į rinką. Tai pigesni esamų vaistų analogai, kuriuos galima parduoti su savo prekės ženklu pasibaigus patento galiojimui. Būtent dėl to kai kurie vaistai turėtų atpigti.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-206-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/23792.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Michał Tomasz Kamiński (ECR), </span></span>  <span class="italic">in writing</span><span class="bold">. −</span> Member States have exclusive competence in deciding on the pricing and reimbursement of medicinal products within their public health insurance systems. However, to ensure a proper functioning of the Single Market, pricing and reimbursement measures must be free of discrimination against imported medicinal products and based on objective and verifiable criteria which are independent from the origin of the products. </p>
<p class="contents">The existing Directive has never been amended since its adoption and its provisions reflect the pharmaceutical market conditions which prevailed more than twenty years ago and which have fundamentally changed, especially with the emergence of generic medicines providing cheaper versions of existing products. In parallel, the constant rise in public expenditure on pharmaceuticals in the last decades has encouraged Member States to invent more complex and innovative pricing and reimbursement systems over time. </p>
<p class="contents">The proposal therefore aims at adapting the Directive to the current pharmaceutical environment while preserving its core foundations. For this reason, I voted in favour of this report.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-206-750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/105849.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Agnès Le Brun (PPE), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> Je me suis prononcée en faveur de ce rapport, qui constituait selon moi un bon compromis entre la proposition initiale de la Commission et la compétence des États membres en matière de fixation des prix et de remboursement des médicaments. La Commission souhaitait en effet par ce texte instaurer des exigences de procédure minimales en la matière visant notamment à faciliter l'accès à des traitements abordables pour tous les patients de l'Union européenne. Pour ce faire, la Commission proposait par exemple d'instaurer des délais pour la fixation des prix et le remboursement des médicaments. Les amendements du Parlement européen ont permis de prolonger et de simplifier ces nouveaux délais, qui seront désormais de 30 jours pour les médicaments génériques et de 90 jours pour les autres.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-207-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/23768.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Bogusław Liberadzki (S&amp;D), </span></span>  <span class="italic">na piśmie</span><span class="bold">. −</span> Leki i wszelkie inne produkty medyczne dla człowieka powinny podlegać właściwej kontroli, tak pod względem ich jakości, jak i dostępności. Dostępność traktować należy w szerokim tego słowa znaczeniu: fizycznym, czyli podaży odpowiedniej ilości w miejscach, do których można dojść lub dojechać, czy ekonomicznym. Dzisiaj zajmujemy się właśnie dostępnością ekonomiczną, czyli przejrzystością w regulowaniu zasad stanowienia cen, tak by leki i produkty medyczne były dostępne cenowo dla każdego potrzebującego człowieka.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-208-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/1403.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">David Martin (S&amp;D), </span></span>  <span class="italic">in writing</span><span class="bold">. −</span> I welcome this report and the proposed 60-day time limit to decide on the pricing and reimbursement of generic medicines, in order to speed up their availability and save money for patients and social security systems. Decisions concerning new medicines will have to respect the current deadline of 180 days. According to the European Commission, generic products are on average 40% cheaper than the original branded medicines, once they have been available for two years. An enquiry showed that companies use various means to extend the period when they can market their medicines exclusively, without competition from generics.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-209-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/4462.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Clemente Mastella (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. −</span> Accogliamo con favore la proposta della Commissione in quanto basata su un'analisi approfondita delle attuali condizioni dei mercati farmaceutici nonché dell'attuale contesto e dei vincoli, soprattutto di natura finanziaria, cui le autorità competenti sono soggette in sede di decisione sulla fissazione del prezzo e sul rimborso dei medicinali.</p>
<p class="contents">Riteniamo che l'obiettivo generale di tale proposta dovrebbe essere quello di aggiornare il quadro legislativo esistente, al fine di chiarire gli obblighi procedurali che incombono agli Stati membri, garantire il buon funzionamento del mercato unico e l'efficacia della legislazione in materia di mercato interno, allo scopo di evitare ingiustificabili ritardi nelle decisioni in materia di fissazione dei prezzi e di rimborso e prevenendo la comparsa di ostacoli agli scambi di medicinali.</p>
<p class="contents">Pur rispettando la competenza esclusiva degli Stati membri nel decidere sulla fissazione del prezzo e sul rimborso dei medicinali, i requisiti procedurali minimi dovrebbero altresì garantire certezza giuridica e trasparenza per le autorità nazionali competenti, promuovere la produzione di medicinali e l'entrata sul mercato di medicinali generici e incoraggiare la ricerca e lo sviluppo di nuovi medicinali, con il fine ultimo di facilitare l'accesso a cure a prezzi sostenibili per tutti i pazienti in Europa.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-209-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/4412.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Véronique Mathieu (PPE), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> J'ai voté en faveur du projet de directive afin d'accroître la transparence des mesures régissant la fixation des prix des médicaments à usage humain. Le délai pour qu'un Etat membre décide du prix et du remboursement des médicaments génériques a été diminué à 60 jours en vue d'améliorer la disponibilité de ces produits. La proposition de texte devrait garantir des conditions de transparence minimales dans l'ensemble de l'Union européenne.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-209-625"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96978.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Nuno Melo (PPE), </span></span>  <span class="italic">por escrito</span>. <span class="bold">−</span> Julgo que o objetivo principal da presente proposta deverá ser a atualização e melhoria do quadro legislativo existente para se clarificarem as obrigações processuais que incumbem aos Estados-Membros, assegurando o bom funcionamento do Mercado Único, bem como a eficácia da legislação relativa ao mercado interno, no que diz respeito à prevenção de atrasos nas decisões sobre a fixação de preços e reembolsos e de obstáculos ao comércio de produtos farmacêuticos. É de insistir na necessidade de reforçar as disposições relacionadas com a transparência do processo de tomada de decisões e com as decisões tomadas, que representa uma crescente exigência da sociedade, nomeadamente quando se trata da fixação de preços e reembolsos de produtos farmacêuticos. Daí o meu voto favorável.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-209-750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28407.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Willy Meyer (GUE/NGL), </span></span>  <span class="italic">por escrito</span><span class="bold">. −</span> Esta directiva pretende imponer a los Estados miembros plazos para decidir los precios y los reembolsos de los medicamentos, con el objetivo de eliminar las barreras de acceso al mercado farmacéutico. Ahora bien, el objetivo de la propuesta legislativa de la Comisión no es garantizar que los residentes en la Unión Europea tengan acceso a una sanidad universal y a los medicamentos de forma gratuita, sino más bien imponer una serie de requisitos a los Estados miembros en materia de precios y reembolsos que, con el loable pretexto de garantizar la transparencia, en la práctica supondrán un sometimiento a los intereses de la industria farmacéutica y la posibilidad de que ésta pueda imponer unilateralmente sus precios a los Estados. Por ello, he votado en contra de este informe, con la voluntad de oponerme al avance del desmantelamiento, encarecimiento y precarización de los servicios públicos sanitarios en la Unión Europea.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-209-875"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96999.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Alexander Mirsky (S&amp;D), </span></span>  <span class="italic">in writing</span><span class="bold">. −</span> The Commission proposal is based on an accurate analysis of current conditions on the pharmaceutical markets as well as of the current context and constraints, notably financial, under which competent authorities have to decide on the pricing and reimbursement of medicinal products. Not rare case when pharmaceutical companies cheat customers through commercials. The control over production and sale of medicines should be increased to the maximum extent possible. I voted in favour.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-210-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28255.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Andreas Mölzer (NI), </span></span>  <span class="italic">schriftlich</span>. <span class="bold">−</span> Mit der Richtlinie zur Preisfestsetzung bei Humanarzneimitteln sollten veraltete Transparenzauflagen für alle Maßnahmen der Preisfestsetzung und Kostenerstattung von Arzneimitteln in den Mitgliedsstaaten an die heutige Zeit angepasst werden, ohne die Verantwortung dieser für das öffentliche Gesundheitswesen und die Finanzierung zu beeinträchtigen. Zudem wurde festgelegt, dass die Preise für Arzneimittel EU-weit gleich sein sollen, und auch die Zulassungsverfahren sollten vereinheitlicht werden. Die Idee dahinter ist, dass der Binnenmarkt für Arzneimittel lückenlos erschlossen werden kann und eine Chancengleichheit auf dem Markt besteht. Der Bericht hat meine Stimme nicht erhalten, da ich der Ansicht bin, dass jeder Mitgliedstaat nach wie vor ein Recht darauf haben sollte, vor allem was die Zulassung von Medikamenten betrifft, selbst entscheiden zu können, nach welchen Kriterien eine Arznei zugelassen wird. Da die Vorschriften in den Ländern divergieren, sollten sie auch selbstständig über den Zulassungszeitpunkt entscheiden können.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-210-250"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96695.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Radvilė Morkūnaitė-Mikulėnienė (PPE), </span></span>  <span class="italic">raštu</span><span class="bold">. −</span> Balsavau už šį dokumentą, nes manau, jog būtina užtikrinti, kad sprendimai, kuriais nustatomos vaistų kainos ir kompensavimo dydžiai, būtų priimami laiku ir skaidriai, kruopščiai kuriama pusiausvyra tarp prievolės išsaugoti valstybių narių kompetenciją visuomenės sveikatos apsaugos srityje ir būtinybės užtikrinti direktyvos veiksmingumą siekiant vidaus rinkos tikslų. Pritariu pranešėjos siūlymams, kad reikia sutvirtinti nuostatas, susijusias su sprendimų priėmimo proceso ir priimamų sprendimų skaidrumu, kurio poreikis visuomenėje auga, ypač vaistų kainų ir kompensavimo atveju. Todėl, manau, ypač teisingas siūlymas nustatyti prievolę kompetentingoms institucijoms atskleisti ekspertų, kurie yra jų sprendimus priimančių institucijų nariai, pavardes ir interesų deklaracijas. Tikiu, kad tokiomis nuostatomis ir padidintu dokumentų ir informacijos viešinimu bus pagerintas priimtų sprendimų skaidrumas, principingumas ir nepriklausomumas.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-210-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/26829.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Siiri Oviir (ALDE), </span></span>  <span class="italic">kirjalikult</span><span class="bold">. −</span> Toetasin oma fraktsioonikaaslase hästi koostatud raportit, pidades oluliseks patsientide kiiremat ligipääsu odavamatele geneerilistele ravimitele. Praegune olukord, kus ravimite hinna kujundamine ja maksumuse hüvitamise otsuste tegemine võib viibida mõnikord mitu aastat, ei ole kindlasti vastuvõetav ning geneeriliste ravimite hinnakujunduse ja hüvitamisprotsessi lühendamine kuni 60 päevani on igati mõistlik ajaperiood. Selleks et vastav otsustamisprotsess oleks läbipaistev ja aus, on ravikomisjonide liikmete nimede ja huvide deklaratsioonide avaldamine möödapääsmatu. Pean minimaalsete Euroopa menetlusnõuete kehtestamist vajalikuks, et tagada pädevate asutuste õiguskindlus ja ergutada uute ravimite uurimist ja väljatöötamist, hoolimata asjaolust, et antud valdkond on liikmesriikide ainupädevuses. Lõppeesmärgiks on siiski taskukohase hinnaga ravi muutmine kõigile Euroopa patsientidele hõlpsamini kättesaadavaks.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-210-750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96694.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Rolandas Paksas (EFD), </span></span>  <span class="italic">raštu</span><span class="bold">. −</span> Balsavau už šią rezoliuciją, kadangi tik bendromis pastangomis galime palengvinti vaistų vidaus rinkos veikimą. Tam, kad būtų užtikrintas laisvas vaistų judėjimas ir teisingas jų kainų nustatymas, reikia pašalinti prekybos farmacijos produktais kliūtis. Labai svarbu užtikrinti, kad vartotojai galėtų efektyviai ir operatyviai pasinaudoti teisių gynimo priemonių procedūromis. Visų pirma, reikia nustatyti veiksmingas priemones, kurios užtikrintų greitą pažeidimų sprendimą tarpininkavimo būdu. Tokiu būdu būtų užkirstas kelias sprendimų dėl kainų nustatymo ir kompensavimo vilkinimui. Antra, toks reglamentavimas padės apsaugoti pacientus ir prisidės prie sveikatos sistemų veiksmingumo ir tvarumo. Tinkamai įgyvendinus direktyvoje nustatytas priemones, turėtų būti sumažintos visų vaistų arba tam tikrų kategorijų vaistų kainos.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-210-875"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28279.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Justas Vincas Paleckis (S&amp;D), </span></span>  <span class="italic">raštu</span><span class="bold">. −</span> Vaistų kainas reglamentuojantys ES teisės aktai skaičiuoja jau 25 metus. Šiuo metu finansinis valstybių narių sveikatos priežiūros sistemų tvarumas nepakelia ekonominės krizės ir biudžetų karpymo politikos naštos. Farmacijos rinka bei pacientų poreikiai per šį laikotarpį labai pasikeitė, todėl reikalingas atnaujintas pažangesnis šios srities teisinis reglamentavimas, didesnis skaidrumas. Balsavau už šį pranešimą, kadangi jis yra naudingas ne tik valstybėms narėms, bet ir pacientams, o taip pat daug darbo vietų sukuriančiai farmacijos pramonei. Pacientams svarbi skaidresnė vaistų kainų nustatymo sistema, pagal kurią jie gautų reikiamus vaistus pigiau ir greičiau. Valstybėms svarbu sutaupyti daugiau biudžeto lėšų, o tai garantuos generinių vaistų plėtra rinkoje.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-210-937"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/97197.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Alfredo Pallone (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. −</span> Ho votato positivamente la relazione che modifica la direttiva 89/105/CEE sulla trasparenza delle misure che regolano la fissazione dei prezzi delle specialità medicinali per uso umano e la loro inclusione nei regimi nazionali di assicurazione perché, osservando l'evoluzione del mercato, anche quello farmaceutico ha bisogno di controlli e regole che assicurino equità e trasparenza per tutti i cittadini a seconda delle politiche nazionali. Gli Stati membri devono applicare immediatamente la nuova direttiva che fisserà i prezzi dei medicinali in ogni Paese facilitando la scelta dei cittadini.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-211-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/97050.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Αντιγόνη Παπαδοπούλου (S&amp;D), </span></span>  <span class="italic">γραπτώς</span><span class="bold">. –</span> Υπερψήφισα την έκθεση γιατί πιστεύω πως είναι αναγκαίος ο εκσυγχρονισμός του νομοθετικού πλαισίου που διέπει τις αγορές φαρμακευτικών προϊόντων καθώς επίσης του πλαισίου τιμολόγησης φαρμάκων. Οι ασθενείς πρέπει να έχουν ταχύτερη πρόσβαση σε φθηνότερα φάρμακα. Τα εθνικά συστήματα υγείας, η ίδια η ενιαία αγορά αλλά κυρίως οι ασθενείς, θα ωφεληθούν ιδιαίτερα, αν οι αρμόδιες αρχές στις χώρες μέλη της ΕΕ, ενισχύσουν τη διαφάνεια στη διαδικασία λήψης αποφάσεων για την τιμολόγηση των φαρμάκων καθώς επίσης την ακεραιότητα ώστε να αποκαλύπτονται τυχόν εμπλεκόμενα συμφέροντα. Οι ορθές πρακτικές πρέπει να ακολουθούνται πιστά.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-211-375"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96900.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Γεώργιος Παπανικολάου (PPE), </span></span>  <span class="italic">γραπτώς</span><span class="bold">. –</span> Γενικός στόχος της παρούσας πρότασης είναι ο εκσυγχρονισμός του κείμενου νομοθετικού πλαισίου ώστε να διευκρινιστούν οι διαδικαστικές υποχρεώσεις των κρατών μελών για την αποτροπή εμποδίων στις συναλλαγές φαρμακευτικών προϊόντων. Υπενθυμίζεται ότι αποτελεί αποκλειστική αρμοδιότητα των κρατών μελών η τιμολόγηση και επιστροφή των δαπανών των φαρμάκων· ωστόσο, επιβάλλεται η θέσπιση ελάχιστων προβλέψεων που θα διασφαλίζουν την ασφάλεια δικαίου και τη διαφάνεια για τις αρμόδιες εθνικές αρχές σχετικά με την παραγωγή φαρμάκων και τη διάθεση στην αγορά γενόσημων φαρμάκων. Το Ευρωπαϊκό Κοινοβούλιο, με την παρούσα έκθεση την οποία και υπερψήφισα, τάσσεται υπέρ της προσέγγισης που προτείνει η Ευρωπαϊκή Επιτροπή όσον αφορά την πρόβλεψη διττών και διαφοροποιημένων προθεσμιών για την τιμολόγηση και την επιστροφή των δαπανών των φαρμάκων, ενώ παράλληλα παρέχεται κίνητρο για την εφαρμογή της αξιολόγησης της τεχνολογίας υγείας που θα ενισχύσει τον καθορισμό ασφαλών και αποτελεσματικών πολιτικών στον τομέα της υγείας που θέτουν στο επίκεντρό τους ασθενείς και επιδιώκουν την επίτευξη βέλτιστης τιμής.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-211-750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96902.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Maria do Céu Patrão Neves (PPE), </span></span>  <span class="italic">por escrito</span>. <span class="bold">−</span> Votei favoravelmente a presente proposta de diretiva do Parlamento Europeu e do Conselho relativa à transparência das medidas que regulamentam os preços dos medicamentos para uso humano e a sua inclusão nos sistemas nacionais de seguro de saúde por concordar com a proposta da Comissão e as suas principais disposições. Destaco das principais disposições desta proposta a análise exata das condições atuais dos mercados farmacêuticos, bem como do contexto e das limitações atuais, nomeadamente financeiras, para definir o quadro ao abrigo do qual as autoridades competentes têm de deliberar sobre a fixação de preços e reembolsos dos medicamentos. Parece-me ser uma estratégia bem pensada e adequada.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-211-875"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96903.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Paulo Rangel (PPE), </span></span>  <span class="italic">por escrito</span>. <span class="bold">−</span> O objetivo geral da presente proposta de diretiva é a atualização do quadro legislativo existente, adaptando-o ao atual quadro farmacêutico e mantendo os princípios fundamentais da diretiva em vigor com as seguintes adaptações: clarificação do âmbito de aplicação; maior clarificação da relação entre as decisões de fixação de preços com os direitos de propriedade intelectual e resultante procedimento de autorização de introdução no mercado; introdução de requisitos adicionais que asseguram maior transparência (v.g. a disponibilização ao público de informações e documentos); e ajustamentos e aditamentos às disposições relativas aos prazos propostas pela Comissão, a fim de garantir uma execução prática e eficaz das disposições previstas e conferir às autoridades nacionais competentes o nível necessário de flexibilidade e autonomia. O objetivo último da adoção de um quadro de requisitos processuais mínimos é facilitar o acesso a tratamentos financeiramente acessíveis a todos os doentes da Europa, reforçando a confiança nas autoridades responsáveis a nível nacional. Do conjunto de medidas adicionais sugeridas pela relatora, destaca-se a obrigação das autoridades competentes de divulgar os nomes e as declarações de interesses dos peritos que sejam membros dos órgãos de decisão afetos. Votei favoravelmente o relatório.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-212-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/97199.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Crescenzio Rivellini (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. −</span> Si è votata oggi in Plenaria la relazione dell'on. Parvanova volta a garantire l'accesso dei pazienti a trattamenti medici più convenienti. Il progetto introduce maggiore trasparenza e limiti precisi entro i quali i paesi dell'UE devono decidere su prezziario e rimborso delle medicine, favorendo così la commercializzazione in maniera più capillare di farmaci generici. L'intenzione non è quella di sostituire i farmaci cosiddetti di marca ma semplicemente di dare la possibilità ai consumatori di poter scegliere.</p>
<p class="contents">La relazione stabilisce un limite di 60 giorni per i paesi membri affinché decidano il prezziario e il rimborso delle medicine generiche, in modo da rendere disponibili più in fretta i prodotti meno cari. Le decisioni sui prezzi e sui rimborsi per le nuove medicine dovranno invece essere prese entro 180 giorni. La nuova legislazione obbliga inoltre le autorità competenti nazionali a divulgare i nomi e le dichiarazioni degli interessi finanziari dei propri membri e consulenti in modo tale che venga garantita la trasparenza e vengano evitate indebite pressioni da parte dei gruppi d'interesse più forti.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-212-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/97022.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Robert Rochefort (ALDE), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> Selon la Commission européenne, les médicaments génériques sont en moyenne 40% moins chers que les produits des marques d'origine. Or les sociétés usent de différents moyens pour allonger la période au cours de laquelle elles peuvent commercialiser leurs produits en exclusivité, sans la concurrence des génériques, ce qui se fait au détriment des patients et des systèmes nationaux de sécurité sociale. Il est nécessaire d'agir pour remédier à cette situation, et j'apporte mon soutien à cette résolution législative qui fixe un délai de 60 jours pour décider du prix et du remboursement des médicaments génériques, en vue d'accélérer la disponibilité de ces produits. En outre, les autorités compétentes dans les États membres devront rendre publics les noms et les déclarations d'intérêt de tous leurs experts et membres, en vue d'assurer la transparence et l'intégrité de leur processus décisionnel, et devront publier, au minimum une fois par an, une liste des médicaments couverts par leur système public d'assurance-maladie avec leur prix. Ces dispositions me paraissent constituer de véritables avancées, et j'espère que les négociations qui vont débuter avec le Conseil aboutiront au plus vite afin de permettre une adoption rapide du texte. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-213-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28409.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Raül Romeva i Rueda (Verts/ALE), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> Abstention. La proposition de la Commission n'était pas acceptable, car largement dominée par les intérêts des industries pharmaceutiques. Il était notamment prévu de raccourcir les délais d'instruction pour la fixation des prix des nouveaux médicaments, ce qui affaiblirait considérablement la qualité des évaluations de ces produits. La directive proposée aurait également fragilisé les missions des institutions d’évaluation de technologie de santé (HTA) et de la Haute autorité de santé qui évalue notamment le service médical rendu par les médicaments. Malgré le travail effectué par la rapporteure Antonyia Parvanova (ALDE), le texte reste flou et n'apporte aucune amélioration au droit existant. Nous avons donc préféré nous abstenir.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-213-750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96755.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Sergio Paolo Francesco Silvestris (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. −</span> Condivido la proposta di direttiva del Parlamento europeo e del Consiglio relativa alla trasparenza delle misure che disciplinano la fissazione dei prezzi dei medicinali per uso umano e la loro inclusione nei regimi pubblici di assicurazione. Sostengo l'opinione secondo cui l'obiettivo generale di tale proposta dovrebbe essere quello di aggiornare il quadro legislativo esistente, al fine di chiarire gli obblighi procedurali che incombono agli Stati membri, garantire il buon funzionamento del mercato unico e l'efficacia della legislazione in materia di mercato interno, evitando ritardi nelle decisioni in materia di fissazione dei prezzi, di rimborso e prevenendo inoltre la comparsa di ostacoli agli scambi di medicinali. I requisiti procedurali minimi dovrebbero invece garantire certezza giuridica e trasparenza per le autorità nazionali competenti, promuovere la produzione di medicinali, l'entrata sul mercato di medicinali generici, incoraggiare la ricerca e lo sviluppo di nuovi medicinali, con il fine ultimo di facilitare l'accesso a cure a prezzi sostenibili per tutti i pazienti in Europa.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-213-875"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/4545.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Catherine Stihler (S&amp;D), </span></span>  <span class="italic">in writing</span><span class="bold">. −</span> I voted in favour as this report proposes more transparency in regulatory measures in pricing medical products used by humans.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-214-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96847.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Claudiu Ciprian Tănăsescu (S&amp;D), </span></span>  <span class="italic">in writing</span><span class="bold">. −</span> I supported the initiative to improve EU citizens’ access to more affordable medicines. Delays in pricing and reimbursements have in some cases reached more than 700 days, which is not to the benefit of EU citizens, especially vulnerable groups coping with chronic diseases. It is essential that Member States provide for more transparency in their decisions regarding generic medicines.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-215-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/29579.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marc Tarabella (S&amp;D), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> Tout en respectant la compétence exclusive des États membres en matière de fixation des prix et de remboursement des médicaments, des exigences de procédure minimales devraient également garantir la sécurité juridique et la transparence pour les autorités nationales compétentes, favoriser la production de médicaments et l'entrée sur le marché de médicaments génériques et encourager la recherche et le développement de nouveaux médicaments, le but final étant de faciliter l'accès à des traitements abordables pour tous les patients en Europe.</p>
<p class="contents">J'insiste en priorité sur la nécessité de renforcer les dispositions relatives à la transparence du processus décisionnel et des décisions adoptées, qui fait l'objet d'une demande croissante de la part de la société, en particulier en ce qui concerne la fixation des prix et le remboursement des produits pharmaceutiques. C'est pourquoi nous avons suggéré une série de mesures supplémentaires, notamment l'obligation pour les autorités compétentes de communiquer les noms et les déclarations d'intérêts des experts membres de leurs organes de décision. Ces dispositions, ainsi qu'une plus grande accessibilité aux documents et aux informations pour le grand public devraient viser à renforcer la transparence, l'intégrité et l'indépendance des décisions prises et devraient, à terme, consolider la confiance dans les autorités publiques compétentes au niveau national.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-215-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96974.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Nuno Teixeira (PPE), </span></span>  <span class="italic">por escrito</span>. <span class="bold">−</span> A atualização da diretiva que regula a transparência em termos de regulamentação dos preços dos medicamentos para uso humano e a sua inclusão nos sistemas nacionais é necessária, uma vez que a atual diretiva data de 1989. Quer isto dizer que a atual legislação não leva em conta as mudanças ocorridas no setor farmacêutico no último quarto de século. Apesar de ser competência exclusiva a regulamentação de preços e os métodos de reembolso do valor dos medicamentos por parte dos Estados-Membros, entendo que uma regulamentação mínima e comum a todos os países deverá existir, de forma a garantir a certeza e transparência jurídica. Tais alterações à diretiva deverão, ainda, garantir a promoção da produção e entrada no mercado de medicamentos genéricos, bem como garantir elevados níveis de investigação e desenvolvimento por parte da indústria farmacêutica no que concerne a novos medicamentos e produtos. Face ao exposto, votei favoravelmente o relatório.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-216-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96858.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marie-Christine Vergiat (GUE/NGL), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> Ce rapport traite de l'autorisation de mise sur le marché d'un médicament avant sa commercialisation. Les règles en vigueur sont destinées à veiller à ce que la qualité, la sécurité et l’efficacité des médicaments soient convenablement évaluées avant qu'ils ne soient délivrés aux patients. </p>
<p class="contents">L'évaluation revient principalement aux États-membres mais certaines conditions élémentaires de transparence doivent être respectées au niveau européen, en particulier les mesures concernant la fixation des prix et le remboursement des médicaments, dont le délai est ici raccourci. </p>
<p class="contents">Mais, sous couvert de transparence, ce rapport donne encore plus de pouvoirs aux industries pharmaceutiques, laissant ces dernières libres de mettre leurs produits sur le marché au prix qu'elles souhaitent quand les autorités ne prennent aucune décision dans les délais considérablement raccourcis. </p>
<p class="contents">L'objectif de mise à disposition rapide de nouveaux traitements ne peut se faire au détriment des malades ni de l'équilibre budgétaire déjà fragile des systèmes publics d'assurance-maladie. Je me suis opposée donc à ce texte comme l'ensemble des députés de mon groupe.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-217-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/30475.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Justina Vitkauskaite (ALDE), </span></span>  <span class="italic">raštu</span><span class="bold">. − </span>Nors turėtų būti gerbiama išskirtinė valstybių narių kompetencija priimant sprendimus dėl vaistų kainų ir jų kompensavimo, žinome, kad tų pačių vaistų kainos skirtingose valstybėse narėse gerokai skiriasi. Farmacininkai paprastai įrodinėja, kad vaistų kaina priklauso nuo šalies, taigi ir rinkos, dydžio, ir kuo šalis didesnė, tuo vaistai joje pigesni. Kaina taip pat skiriasi todėl, kad vienose tie patys vaistai yra kompensuojami, o kitose – ne. Nustatant vaistų kainas valstybėse narėse stinga skaidrumo, todėl paliekama labai daug galimybių neskaidriai kainodarai ir nepagrįstam farmacijos įmonių pelno didinimui.</p>
<p class="contents">Pasisakau už tai, kad turi egzistuoti skaidri vaistų kainos nustatymo sistema. Pritariu 90 dienų laikotarpiui vaisto kainos ir kompensacinio mechanizmo nustatymui. Manau, ilgesniu laikotarpiu bus tinkamai pasiruošta naujo vaisto įvedimui. Manau, kad taip pat būtina sumažinti rinkos kliūtis ir suteikti pacientams galimybes naudotis naujai atrastais vaistais. Reikia užtikrinti, kad ES vaistų agentūra puikiai atliktų savo priežiūros vaidmenį. Pasisakau už didesnį vaistų kainų skaidrumą, o vaistų kainų reguliavimo tarnybos turi suteikti galimybę mums vaistus įsigyti prieinamomis kainomis.</p>
<p class="contents">Sveikinu pranešėją A. Parvanovą su puikiu darbu. Visuomenės sveikata yra didžiulis turtas, o ne našta. ES turi būti skatinami moksliniai tyrimai ir naujų vaistų kūrimas siekiant galutinio tikslo pagerinti visų Europos pacientų galimybes gauti prieinamą gydymą.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-218-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96802.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Jacek Włosowicz (EFD), </span></span>  <span class="italic">na piśmie</span><span class="bold">. −</span> Przepisy Unii zawierają wymóg, aby właściwe organy unijne lub krajowe wydały pozwolenie na dopuszczenie do obrotu zanim jakikolwiek produkt leczniczy będzie mógł zostać wprowadzony do handlu. Chyba nikt nie ma wątpliwości, że życie i zdrowie jest jedną z najważniejszych wartości dla każdego człowieka. Każdy produkt leczniczy dopuszczony do obrotu w UE powinien być dostępny dla pacjentów we wszystkich państwach członkowskich. Przedłużanie procedur ustalania cen i refundacji kosztów przyczynia się do opóźnień we wprowadzaniu produktów leczniczych do obrotu. Może to być szczególnie niekorzystne w przypadku innowacyjnych środków. Konsekwencją tego może być nawet utrata życia bądź jego skrócenie. Dlatego projekt, który zawiera propozycje usunięcia przeszkód w funkcjonowaniu rynku wewnętrznego i poprawę jego działania jest jak najbardziej pożądany.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-218-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/23894.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Anna Záborská (PPE), </span></span>  <span class="italic">písomne</span><span class="bold">. −</span> Na Slovensku v súčasnosti prebieha verejná diskusia o registrácii potratových tabletiek. Boli sme svedkami toho, ako štátne orgány najskôr neinformovali verejnosť a potom zámerne uvádzali a dodnes uvádzajú nesprávne a nepravdivé informácie. Verejnosť nie je informovaná ani o prípadnom konflikte záujmov u tých, ktorí o liekoch rozhodujú. Preto podporujem opatrenia, ktoré povedú k väčšej transparentnosti. Členské štáty majú právo aj povinnosť zabezpečiť pre svojich občanov kvalitné lieky za cenu, ktorá zohľadňuje kúpnu silu. Nová smernica vnesie viac svetla do rozhodovania regulačných orgánov, ktoré rozhodujú o uvedení liekov na trh, ich cene a miere dotácie z verejných zdrojov. To je dôležité nielen z pohľadu jednotného európskeho trhu. Je to predovšetkým v záujme občanov.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-218-625"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96803.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Zbigniew Ziobro (EFD), </span></span>  <span class="italic">na piśmie</span><span class="bold">. −</span> Unia Europejska nie powinna ustalać odgórnie jakichkolwiek cen produktów leczniczych. Rozumiem potrzebę wspólnego rynku, jednak ceny tak podstawowych produktów powinna regulować ręka rynku, nie unijna dyrektywa. Jednocześnie wśród zgłaszanych poprawek znalazło się wiele cennych uwag, które w swoim głosowaniu poparłem. Wspomniane minimalne wymogi proceduralne powinny również gwarantować pewność prawną i zachowywanie przez właściwe organy przejrzystości w procesie podejmowania decyzji dotyczących cen produktów leczniczych oraz ich refundacji przez systemy powszechnego ubezpieczenia zdrowotnego-to ważne zdanie wskazuje na bolączkę obecną wśród państw członkowskich a jest nią uległość wobec farmaceutycznych lobbystów. W moim kraju wielokrotnie ujawniano korupcję oraz nieścisłości przy kontraktowaniu leków ustalaniu listy leków refundowanych.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-218-750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/111589.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Inês Cristina Zuber (GUE/NGL), </span></span>  <span class="italic">por escrito</span>. <span class="bold">−</span> Os Estados-Membros são responsáveis pela organização dos respetivos sistemas de saúde e pela repartição dos recursos que lhe são afetados, incluindo na área dos medicamentos. Assim é e assim deve continuar a ser. A proposta da relatora, no seguimento da proposta da Comissão Europeia, a pretexto da necessária transparência na fixação do preço dos medicamentos (que não contestamos) e dos desenvolvimentos ao nível do setor farmacêutico – com desenvolvimento de novos medicamentos –, acaba por submeter os Estados-Membros e os interesses dos cidadãos aos interesses da indústria farmacêutica. Caso os prazos agora estabelecidos para os Estados-Membros decidirem sobre o preço e sobre o sistema de reembolso de cada medicamento não sejam cumpridos, a indústria farmacêutica tem, no limite, o poder de impor unilateralmente o seu preço aos Estados. A proposta implica ainda limitações, que consideramos graves, da soberania dos Estados-Membros, nos domínios da reavaliação da segurança, eficácia e qualidade dos medicamentos.</p></td><td width="16"> </td></tr></table></td></tr></table><table width="100%" border="0" cellspacing="0" cellpadding="5"><tr class="footerdocwin"><td></td><td align="right"><a target="_blank" href="/legal-notice/en">Legal notice</a> - <a target="_blank" href="/privacy-policy/en">Privacy policy</a></td></tr></table></td></tr></table></body></html>
